Holdings
Propel Bio Management, LLC
As of Sep 30, 2026, Propel Bio Management, LLC reported 29 positions worth US$186M. Largest: Plains GP Holdings, L.P., Achieve Life Sciences, Inc. and Delcath Systems, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Plains GP Holdings, L.P. | 1.27M | US$33M | no change | Sep 30, 2026 |
| Achieve Life Sciences, Inc. | 3.86M | US$31.3M | −170K | Sep 30, 2026 |
| Delcath Systems, Inc. | 605K | US$9.66M | −267K | Sep 30, 2026 |
| Collegium Pharmaceutical, Inc. | 410K | US$8.95M | new | Sep 30, 2026 |
| Corcept Therapeutics Incorporated | 75,274 | US$8.67M | −61,225 | Sep 30, 2026 |
| Aquestive Therapeutics, Inc. | 279K | US$8.61M | −1.16M | Sep 30, 2026 |
| Milestone Pharmaceuticals Inc. | 9.45M | US$8.18M | +2.02M | Sep 30, 2026 |
| Phathom Pharmaceuticals, Inc. | 1.11M | US$8.07M | +55,555 | Sep 30, 2026 |
| COMPASS Pathways Plc | 549K | US$6.83M | new | Sep 30, 2026 |
| Orchestra BioMed Holdings, Inc. | 897K | US$5.58M | no change | Sep 30, 2026 |